Related Experiment Video
Updated: May 12, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
CD95 in cancer: tool or target?
Ana Martin-Villalba1, Enric Llorens-Bobadilla, Damian Wollny
1Molecular Neurobiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. a.martin-villalba@dkfz.de
Abstract:
The role of CD95 (Fas/Apo1) in cancer has been a matter of debate for over 30 years. First discovered as an apoptosis-inducing molecule, CD95 soon emerged as a potential anticancer therapy. Yet accumulating evidence indicates a profound role for CD95 in alternative nonapoptotic signaling pathways that increase tumorigenesis. This fact challenges the initial clinical idea of using CD95 as a 'tumor killer' while setting the stage for clinical studies targeting the nonapoptotic signaling branch of CD95. This review summarizes the findings surrounding manipulation of the CD95 pathway for cancer therapy, considering how one receptor can both promote and prevent cell growth.
Insights
The CD95 receptor
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- The CD95 (Fas/Apo1) receptor's role in cancer has been debated for over 30 years.
- Initially recognized for inducing apoptosis, CD95 was considered a potential anticancer therapy.
- Emerging evidence highlights CD95's involvement in nonapoptotic pathways promoting tumorigenesis.
Purpose of the Study:
- To review the dual role of CD95 signaling in cancer.
- To discuss the implications of CD95's pro-tumorigenic functions for cancer therapy.
- To explore targeting nonapoptotic CD95 signaling for cancer treatment.
Main Methods:
- Literature review of studies on CD95 signaling in cancer.
- Analysis of research on CD95's apoptotic and nonapoptotic functions.
- Examination of clinical strategies involving CD95 manipulation.
Main Results:
- CD95 exhibits contradictory roles in cancer, capable of both inhibiting and promoting tumor growth.
- Nonapoptotic CD95 signaling pathways are implicated in enhancing tumorigenesis.
- The dual nature of CD95 challenges its use as a simple 'tumor killer'.
Conclusions:
- Targeting the nonapoptotic signaling branch of CD95 presents a novel therapeutic strategy.
- Understanding CD95's complex roles is crucial for developing effective cancer treatments.
- Future clinical studies should focus on modulating specific CD95 signaling pathways.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...